Current evidence on Type 2 inflammation supports the united airway disease concept (coexistence of upper and lower respiratory tract diseases in the same patient), with common physiopathological and therapeutic grounds. Current guidelines are changing towards a multidisciplinary approach, recommending treatments that would wholly address the common underlying inflammation, but there is no consensus yet on how to put this in practice, nor clear biomarkers to predict good response to the several treatments available, mainly T2- targeting biologicals.
The aim of this Research Topic is mainly to revise the state of the art, reveal cutting edge research and approaches of this new paradigm in CAD, and put together expert opinions upon the change in paradigm that we will be witnessing in the following 5 years in asthma, COPD and Chronic rhinosinusitis guidelines. Experts from different specialties will be invited to participate (allergy pulmonology, ENT, immunology specialists mainly).
This Research Topic calls for papers on, but not limited to, the following themes:
- Original articles, Brief Research Reports, Expert opinion or reviews that address severe asthma and its comorbidities, preferably from a molecular perspective, providing new knowledge on biomarkers or novelty treatments, supported by molecular medicine applicable to these complex diseases, especially biologics.
- Focus on cellular and immunological mechanisms, as well as new biomarkers i.e. radiology/ advanced lung imaging.
- New developments in severe asthma management, including targeted treatments and development of precision medicine
Current evidence on Type 2 inflammation supports the united airway disease concept (coexistence of upper and lower respiratory tract diseases in the same patient), with common physiopathological and therapeutic grounds. Current guidelines are changing towards a multidisciplinary approach, recommending treatments that would wholly address the common underlying inflammation, but there is no consensus yet on how to put this in practice, nor clear biomarkers to predict good response to the several treatments available, mainly T2- targeting biologicals.
The aim of this Research Topic is mainly to revise the state of the art, reveal cutting edge research and approaches of this new paradigm in CAD, and put together expert opinions upon the change in paradigm that we will be witnessing in the following 5 years in asthma, COPD and Chronic rhinosinusitis guidelines. Experts from different specialties will be invited to participate (allergy pulmonology, ENT, immunology specialists mainly).
This Research Topic calls for papers on, but not limited to, the following themes:
- Original articles, Brief Research Reports, Expert opinion or reviews that address severe asthma and its comorbidities, preferably from a molecular perspective, providing new knowledge on biomarkers or novelty treatments, supported by molecular medicine applicable to these complex diseases, especially biologics.
- Focus on cellular and immunological mechanisms, as well as new biomarkers i.e. radiology/ advanced lung imaging.
- New developments in severe asthma management, including targeted treatments and development of precision medicine
